Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
| Autor: | Venter, Willem D F *, Sokhela, Simiso, Simmons, Bryony, Moorhouse, Michelle, Fairlie, Lee, Mashabane, Nkuli, Serenata, Celicia, Akpomiemie, Godspower, Masenya, Masebole, Qavi, Ambar, Chandiwana, Nomathemba, McCann, Kaitlyn, Norris, Shane, Chersich, Matthew, Maartens, Gary, Lalla-Edward, Samanta, Vos, Alinda, Clayden, Polly, Abrams, Elaine, Arulappan, Natasha, Hill, Andrew |
|---|---|
| Zdroj: | In The Lancet HIV October 2020 7(10):e666-e676 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|